Resolution of Late Steroid-Responsive Nephrotic Syndrome in a Patient with Alport Syndrome Treated with Atorvastatin

Jia-Feng Chang¹,², Wei-Ning Lin¹, Chien-Chen Tsai³*

¹Graduate Institute of Basic Medicine, Fu Jen Catholic University, Taipei, Taiwan
²Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
³Department of Anatomic Pathology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
Email: *cjf6699@yahoo.com.tw

Received 3 January 2015; accepted 29 January 2015; published 2 February 2015

Abstract

Experimental and clinical studies have pointed out the lipid-induced renal damage, and statins may have pleiotropic effects on renoprotection. We reported a girl with X-linked Alport syndrome whose late steroid-responsive nephrotic syndrome (NS) was resolved by atorvastatin. She had been in a nephrotic condition despite prednisone therapy 60 mg/day for 8 weeks. Renal biopsy disclosed extreme foamy appearance of tubular epithelial cells with detachment leading to luminal obliteration. Atorvastatin was started on the ninth week of prednisone therapy due to severe hypercholesterolemia. Partial remission of NS was dramatically achieved with unchanged dosage of prednisone at the end of the twelfth week. Our case provides a pathology-based evidence to support the use of statins in profoundly hyperlipidemic patients with NS. In patients with NS and profound hyperlipidemia, early initiation of statin therapy is required in combination with immunosuppressive therapy.

Keywords

Nephrotic Syndrome, Statin

1. Introduction

Experimental and clinical studies have pointed out the lipid-induced renal damage [1], and statins may have pleiotropic effects on renoprotection. We reported a girl with X-linked Alport syndrome whose late steroid-responsive nephrotic syndrome (NS) was resolved by atorvastatin. She had been in a nephrotic condition despite prednisone therapy 60 mg/day for 8 weeks. Renal biopsy disclosed extreme foamy appearance of tubular epithelial cells with detachment leading to luminal obliteration. Atorvastatin was started on the ninth week of prednisone therapy due to severe hypercholesterolemia. Partial remission of NS was dramatically achieved with unchanged dosage of prednisone at the end of the twelfth week. Our case provides a pathology-based evidence to support the use of statins in profoundly hyperlipidemic patients with NS. In patients with NS and profound hyperlipidemia, early initiation of statin therapy is required in combination with immunosuppressive therapy.

pleiotropic effects on renoprotection [2]. Lowering serum concentrations of cholesterol and triglycerides by lipid-apheresis or statin therapy improves the response to steroids in pediatric nephrotic syndrome (NS) [3]-[6]. We reported the case of a girl with X-linked Alport syndrome whose late steroid-responsive nephrotic syndrome (NS) was resolved by atorvastatin. To our best knowledge, there was no study showing pathology-based evidence to support the use of statins in profoundly hyperlipidemic patients with NS.

2. Case Report

A 12-year-old girl presented with puffy face, bilateral lower-leg edema and frothy urine in recent two months. Biochemical studies showed nephrotic range proteinuria, hematuria > 30 erythrocytes per high-power field, lipiduria, serum cholesterol 10.1 mmol/l, albumin 16 g/l, and creatinine 30.5 mmol/l. Her blood pressure was 108/70 mmHg, and renin-angiotensin system blockers were not used. A kidney biopsy was performed for her nephrotic-nephritic syndrome with unclear etiology. Light microscopic examination with hematoxylin and eosin stain revealed rigidity and moderate thickening of the glomerular basement membrane (GBM), and segmental glomerular sclerosis. Accumulating an excessive amount of neutral fats in renal tubular cells led to extremely foamy appearance and luminal obliteration (Figure 1). Such fatty change is followed by necrosis of injured cells and detachment from the basement membranes compounding luminal obliteration. Electron microscopy depicted irregular distribution of GBM with basket-weave appearance (thinning, thickening, splitting and lamination of lamina densa) and diffuse effacement of podocyte foot processes (Figure 2). Myriad intracellular lipid droplets were noted within tubulointerstitial lipid-laden foamy macrophages (Figure 3).

The pathological finding pointed out the burden of lipid-induced renal damage. Compatible with her renal pathology, she had been in a nephrotic condition despite of prednisone therapy 60 mg/day for 8 weeks. Atorvastatin was started at a dose of 10 mg/day on the ninth week of prednisone therapy due to her progressive hypercholesterolemia (16.0 mmol/l). Partial remission of NS (proteinuria < 3 g/24 h) was dramatically achieved at the end of the twelfth week. The dosage of prednisone (60 mg/day) had not been changed since the inclusion of atorvastatin. Therefore, atorvastatin may resolve proteinuria by improving hyperlipidemia and lipid-induced renal damage.

3. Discussion

Studies have reported statins have pleiotropic effects on improving glomerular damage, preventing glomerulosclerosis and tubulointerstitial fibrosis [2]. Lowering serum concentrations of cholesterol and triglycerides by lipid-apheresis or statin therapy improves the response to steroids in pediatric NS [3]-[6]. In obese animal models,
lipid accumulation in kidneys accentuated glomerulosclerosis and proteinuria [7]. Compared with non-treated obese animals, statins attenuated lipid accumulation in the proximal tubules and reduced glomerular hypertrophy [8]. In experimental anti-glomerular basement membrane glomerulonephritis, the anti-proteinuric effect of atorvastatin is mediated through anti-inflammatory responses [9] [10].

To our best knowledge, this is the first case of a hyperlipidemic patient whose late steroid-responsive NS was resolved by atorvastatin with a pathology-based evidence of lipid-induced kidney injury. The renal pathology revealed extremely foamy tubular cells and detachment of injured cells from the basement membranes. Such results led to obliterate renal tubular lumens, increased intratubular pressure, tubulointerstitial edema and de-
creased glomerular filtration rate. Thus we initiated atorvastatin in this patient to treat her progressive hypercholesterolemia and lipid-induced kidney injury. Her nephritic range proteinuria and severe hypercholesterolemia were significantly ameliorated with atorvastatin, accompanied with elevated serum albumin level and edema resolution. The baseline therapeutic doses of prednisone and diuretic regimen were not changed. The reasons why the combination therapy of prednisone and atorvastatin became more effective for NS included but not limited to the following. On one hand, statins have direct anti-proteinuric effects on both podocytes and renal tubular epithelial cells by preventing oxidized low-density lipoprotein-induced damage [11] [12]. On the other hand, pleiotropic effects of statins include modification of endothelial function, immunomodulation and anti-inflammation [13]. Based on the pathological evidence, atorvastatin may have an effect on ameliorating the extremely foamy change of renal tubular cells with subsequent apoptosis, and thereby relieving renal tubular obstruction. The appropriateness of statins in pediatric patients is the major concern [14]. Adverse effects of statins, such as muscle injury and liver toxicity, were not found in our patient. Study reported short-term use of statins is safe and efficient in the hyperlipidemic pediatric patients, but long-term safety is unknown [15]. Implementing statin therapy in children with nephrotic syndrome should be carefully followed up [16].

4. Conclusion

Our case provided a pathology-based evidence to support the use of statins in profoundly hyperlipidemic patients with NS. It suggests statins have anti-proteinuric effects by lowering lipid-induced renal damage and improve the response to steroid treatment. In profoundly hyperlipidemic patients with NS, early initiation of statin therapy is required in combination with immunosuppressive therapy.

References


Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or Online Submission Portal.